Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Diabetes/Metabolism Research and Reviews|January 25, 2014
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatmentThomas Forst, Ernestos Anastassiadis, Stephan Diessel, et al.
Cardiovascular Diabetology|July 16, 2011
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB studyMarkolf Hanefeld, Andreas Pfützner, Thomas Forst, et al.
British Journal of Clinical Pharmacology|March 30, 2007
Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic painThomas Forst, Terry Smith, Klemens Schütte, et al.
Journal of Hypertension|November 25, 2015
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patientsThomas Forst, Georg Michelson, Stephan Diessel, et al.
Journal of Diabetes Science and Technology|July 29, 2010
Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3Volkmar Schmid, Cloth Hohberg, Marcus Borchert, et al.
Clinical Laboratory|November 16, 2005
Biological background and role of adiponectin as marker for insulin resistance and cardiovascular riskThomas Schöndorf, Agnes Maiworm, Neil Emmison, et al.
Journal of Diabetes Science and Technology|November 6, 2009
Self-monitoring of blood glucose levels requires intensive training for use of meters to obtain reliable and clinically relevant measurementsThomas A Mohr, Andreas Pfützner, Senait Forst, et al.
BMC Psychiatry|November 3, 2011
Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational studySusanne Kraemer, Anette Minarzyk, Thomas Forst, et al.
The Review of Diabetic Studies : RDS|December 30, 2009
Molecular effects of C-Peptide in microvascular blood flow regulationThomas Forst, Thomas Hach, Thomas Kunt, et al.
Journal of Diabetes Science and Technology|July 10, 2012
In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatmentStefan Pscherer, Martin Larbig, Berndt von Stritsky, et al.
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Diabetes/Metabolism Research and Reviews|January 25, 2014
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatmentThomas Forst, Ernestos Anastassiadis, Stephan Diessel, et al.
Cardiovascular Diabetology|July 16, 2011
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB studyMarkolf Hanefeld, Andreas Pfützner, Thomas Forst, et al.
British Journal of Clinical Pharmacology|March 30, 2007
Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic painThomas Forst, Terry Smith, Klemens Schütte, et al.
Journal of Hypertension|November 25, 2015
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patientsThomas Forst, Georg Michelson, Stephan Diessel, et al.
Journal of Diabetes Science and Technology|July 29, 2010
Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3Volkmar Schmid, Cloth Hohberg, Marcus Borchert, et al.
Clinical Laboratory|November 16, 2005
Biological background and role of adiponectin as marker for insulin resistance and cardiovascular riskThomas Schöndorf, Agnes Maiworm, Neil Emmison, et al.
Journal of Diabetes Science and Technology|November 6, 2009
Self-monitoring of blood glucose levels requires intensive training for use of meters to obtain reliable and clinically relevant measurementsThomas A Mohr, Andreas Pfützner, Senait Forst, et al.
BMC Psychiatry|November 3, 2011
Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational studySusanne Kraemer, Anette Minarzyk, Thomas Forst, et al.
The Review of Diabetic Studies : RDS|December 30, 2009
Molecular effects of C-Peptide in microvascular blood flow regulationThomas Forst, Thomas Hach, Thomas Kunt, et al.
Journal of Diabetes Science and Technology|July 10, 2012
In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatmentStefan Pscherer, Martin Larbig, Berndt von Stritsky, et al.
Pageof 15